Clinical trials: Head and Neck Tumours
Oral Mucositis
Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the duration or length of severe oral mucositis in patients with head and neck cancers.
- Trial name
- PREVLAR (NCT03515538)
- Testing
- RRx-001, Cisplatin for injection, Radiation Therapy
- Where
- 12 sites in United States
- Volunteers
- 53 people
- Sponsor
- EpicentRx, Inc.
Esophageal Cancer, MRD
Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy
Numerous studies have confirmed that ctDNA-MRD detection technology based on peripheral blood can identify minimal residual disease (MRD) following surgery and other curative treatments, indicating a higher risk of recurrence.
- Conditions
- Esophageal Cancer, MRD, ctDNA
- Trial name
- NCT07371247
- Testing
- Step-up therapy, Standard treatment Routine treatment
- Where
- China
- Volunteers
- 65 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
HER2-positive Solid Tumors, HER2-positive Breast Cancer
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies
- Conditions
- HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Colorectal Cancer, HER2-positive Gastroesophageal Cancer
- Trial name
- NCT04278144
- Testing
- BDC-1001, Nivolumab
- Where
- 21 sites in United States, France and 2 more
- Volunteers
- 175 people
- Sponsor
- Bolt Biotherapeutics, Inc.
First Line Chemotherapy, Capecitabine Plus Cisplatin Versus Capecitabine Plus Paclitaxel
Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma
Until today, the 5-FU/cisplatin combination is the reference regimen with 30-45% response rates, which is most commonly used to treat patients with metastatic, recurrent or locally advanced, unresectable squamous cell carcinoma…
- Conditions
- First Line Chemotherapy, Capecitabine Plus Cisplatin Versus Capecitabine Plus Paclitaxel, Advanced or Recurrent Esophageal Squamous Cell Carcinoma
- Trial name
- XP versus XT (NCT00816634)
- Testing
- Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)
- Where
- South Korea
- Volunteers
- 94 people
- Sponsor
- Samsung Medical Center
Esophageal Cancer, Esophageal Neoplasms
Assessment of Response to nCRT for GEJ Cancer Using a Fully Integrated PET/MRI
Evaluate the potential role of PET/MRI as a predictor of esophageal and junctional cancers in response to neoadjuvant chemoradiotherapy (nCRT).
- Trial name
- Escape (NCT04359732)
- Testing
- hybrid PET/MRI
- Where
- Italy
- Volunteers
- 121 people
- Sponsor
- IRCCS San Raffaele
Head and Neck Cancer Survivors, Cancer of the Head and Neck Surviors
Head and Neck Cancer Survivorship Ototoxicity Screening (SOS)
To evaluate the effectiveness, feasibility, acceptability, and appropriateness of an ototoxicity screening protocol among head and neck (H\&N) cancer patients followed in survivorship clinic that received cisplatin-based…
- Trial name
- NCT05789316
- Testing
- Ototoxicity Screening Protocol
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Washington University School of Medicine
Metastatic Pancreatic Cancer, Colorectal Cancer
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
The purpose of this study is to confirm the safety and tolerability of TAK-931 in a cohort of Western participants with metastatic solid tumors and to evaluate the anti-tumor activity of TAK-931 in participants with metastatic…
- Conditions
- Metastatic Pancreatic Cancer, Colorectal Cancer, Esophageal Neoplasms, Carcinoma, Non-small-cell Lung
- Trial name
- NCT03261947
- Testing
- TAK-931
- Where
- 10 sites in United States, Japan
- Volunteers
- 101 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Esophageal Squamous Cell Carcinoma
Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma
This study aims to evaluate the efficacy of Camrelizumab with neoadjuvant chemotherapy for resectable thoracic esophageal squamous cell carcinoma
- Trial name
- NCT04506138
- Testing
- Camrelizumab, Paclitaxel for Injection (Albumin Bound), Carboplatin
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma
This study is to investigate the efficacy and safety of the induction chemotherapy + concurrent chemoradiotherapy（CCRT）combined with toripalimab and endostar treatment, in comparison with the induction chemotherapy + concurrent…
- Trial name
- NCT04447326
- Testing
- Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy, IC＋CCRT
- Volunteers
- 106 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Recurrent or Metastatic Nasopharyngeal Carcinoma
Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma
This is a prospective, single-arm Phase 2 study to evaluate the efficacy and safety of sintilimab combined with anlotinib and taxane-based chemotherapy in patients with recurrent (not unable to locally curative treatment) or…
- Trial name
- NCT07581821
- Testing
- Sintilimab + Anlotinib + taxane-based chemotherapy
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Ming-Yuan Chen
Esophageal Squamous Cell Cancer
Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer
Nimotuzumab, as one new agent used in advanced esophageal carcinoma, has been shown to be effective and safe in some studies with head-neck cancers.
- Trial name
- NCT01336049
- Testing
- Nimotuzumab
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking University
Tonsil Neoplasm, Oropharynx Neoplasm
Buccal Fat for Transoral Robotic Lateral Oropharyngectomy Defects to and Postoperative Pain
The goal of this randomized clinical trial is to determine the pain intensity during rest and swallowing in patients undergoing transoral robotic surgery for tonsil lesions with and without buccal fat reconstruction.
- Conditions
- Tonsil Neoplasm, Oropharynx Neoplasm, Transoral Robotic Surgery
- Trial name
- BOLT (NCT06965738)
- Testing
- Buccal fat reconstruction, No buccal fat reconstruction
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Pleomorphic Adenoma of the Parotid, Warthin Tumor
Identification of Nerves Using Fluorescein Sodium
The purpose of this study is to see if there is benefit in using an IV contrast (sodium fluorescein) to identify nerves during head and neck surgery.
- Conditions
- Pleomorphic Adenoma of the Parotid, Warthin Tumor, Head and Neck Disorder, Head and Neck
- Trial name
- NCT06054178
- Testing
- Fluorescein Sodium
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Stanford University
Head And Neck Cancer
Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia
The goal of this clinical research study is to learn if acupuncture can help to prevent xerostomia (dry mouth) and improve the quality of life in patients who receive radiation treatment to the head and neck.
- Trial name
- NCT01266044
- Testing
- Acupuncture - Group 1, Acupuncture - Group 2, Standard Care
- Where
- 2 sites in United States, China
- Volunteers
- 435 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer
Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection
The goal of this clinical research study is to learn if adding erlotinib to a standard chemotherapy combination (docetaxel and either cisplatin or carboplatin) can help to control SCCHN.
- Trial name
- NCT01927744
- Testing
- Docetaxel, Erlotinib, Questionnaires
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Squamous Cell Carcinoma
Whether it is More Appropriate to Spray Lugol's Solution From Cervical Esophagus to Esophagogastric Junction
The aim of this study is to compare the effectiveness and safety of spraying Lugol's solution from cervical esophagus to esophagogastric junction (downward) and from esophagogastric junction to cervical esophagus （upward）during…
- Trial name
- NCT04224363
- Testing
- staining from cervical esophagus to esophagogastric junction, staining from esophagogastric junction to cervical esophagus
- Volunteers
- 80 people
- Sponsor
- Shandong University
Stent Migration, GastroEsophageal Cancer
Anti-Migration System for Anti-reflux Oeso-gastric Stent (ANTIMIG)
The aim of this prospective, controlled, randomized, multicentre, single-blind study is to compare the rate of intragastric migration of 2 types of esophageal stents with and without an anti-migration device placed for locally…
- Trial name
- ANTIMIG (NCT05431738)
- Testing
- Gastroesophageal stent placement
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Société Française d'Endoscopie Digestive
Head and Neck Neoplasms, Xerostomia
Evaluation of Treatment Related Toxicity After Radiotherapy for Head and Neck Cancer
Radiotherapy plays an important role in the curative treatment of head and neck cancer. This treatment however is associated with significant acute and late toxicity with xerostomia and dysphagia severely implicating the…
- Conditions
- Head and Neck Neoplasms, Xerostomia, Deglutition Disorders
- Trial name
- NCT01621048
- Where
- Belgium
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Esophageal Squamous Cell Carcinoma
A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC
This study is conducted to investigate whether modified chemoradiotherapy with elective nodal irradiation reduces the locoregional recurrence that cannot be completely resected by salvage endoscopic resection and preserve…
- Trial name
- ARMADILLO (NCT04328948)
- Testing
- Chemoradiotherapy
- Where
- Japan
- Volunteers
- 280 people
- Sponsor
- National Cancer Center, Japan
Esophageal Carcinoma, Gastric Carcinoma
Detection of Upper Gastrointestinal Tumour Depth and Demarcation Using Systemic Administration of Indocyanine Green During Endoscopic Submucosal Dissection
Endoscopic submucosal dissection (ESD) is a relatively new technique to treat superficial cancers in the upper gastrointestinal (GI) tract. Previous studies reported high en bloc resection rates (95%-97%).
- Trial name
- BRIGHT (NCT07108855)
- Testing
- Indocyanine Green (IC-Green), Fluorescence guided identification using indocyanine green
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- University Medical Center Groningen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.